Anti-Mitotic Activity and Downstream Immune Response of Tumor Treating Fields (TTFields) Therapy

TTFields employ electrical fields at a frequency of 100-500 kHz. 1,2They enter cancer cells and disrupt processes critical to cell viability, primarily mitosis, with minimal stimulation or heating of the surrounding tissue. 1,2 TTFields therapy targets cancer cells, while sparing healthy cells and tissue. TTFields spare healthy cells because these have different properties from cancer cells, including division rate, morphology, and electrical properties. 1,3,4TTFields induce an anti-mitotic effect, to which rapidly-dividing cancer cells are particularly susceptible compared with quiescent cells. 2 Across solid tumour types, TTFields have been studied with:Experiments in mouse models showed that, compared with monotherapy, TTFields with checkpoint inhibitors (specifically anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies) led to:ANTI-MITOTIC ACTIVITY AND DOWNSTREAM IMMUNE